Chemomab Therapeutics Ltd. (CMMB)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $1.24
- As of
Kresmion compiles this page from CMMB's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Chemomab Therapeutics Ltd. (CMMB): 1 institutional manager tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 6-K filed 2026-09-30.
See the full CMMB dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for CMMB on one page. Preview it with sample data, then open it live with a free account.
Preview the CMMB dossierActive signals for CMMB
- mediumEARNINGS_MISS
Q2-2026: Missed consensus by 56.9%, EPS $-0.24 vs $-0.153 estimate
- mediumEARNINGS_MISS
Q4-2024: Missed consensus by 101.1% - EPS $-0.64 vs $-0.3182 estimate
- lowEARNINGS_MISS
Q1-2025: EPS $-0.56 vs $-0.0408 estimate, -0.52 on a near-zero consensus
- mediumEARNINGS_BEAT
Q4-2025: Beat consensus by 24.1% - EPS $-0.24 vs $-0.3162 estimate
- mediumEARNINGS_MISS
Q1-2026: Missed consensus by 51.8% - EPS $-0.24 vs $-0.1581 estimate
FREE, NO ACCOUNT
Every signal on CMMB, as it fires
New filings, 13F moves and cross asset signals on CMMB land in the record first.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in CMMB (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| CITADEL ADVISORS LLCCUSIP 16385C203 · 2026Q2 | $154K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, CMMB
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 20-FSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
CMMB against its peers
CMMB's return on equity of -72.9% ranks in the 62nd percentile of 16 Biotechnology sub-industry peers, fiscal periods ending between 2025-06-30 and 2026-06-30.
| Metric | CMMB | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | n/a | 1.2M | n/a | 9 |
| Gross margin | n/a | 65.4% | n/a | 5 |
| Operating margin | n/a | -871.8% | n/a | 9 |
| Net margin | n/a | -848.7% | n/a | 10 |
| Return on equity | -72.9% | -152.8% | 62 | 16 |
| 1 year | -63.1% | -54.9% | 43 | 14 |
Peers (22): ADIL, CALC, TOVX, ZEOX, SNTI, MTVA, BCLI, JAGX, OTLC, GTBP, KPRX, INTS, PHIO, BLRX, VTGN, HEPA, ENSC, GDTC, IMRN, ASBP, BIVI, PLUR. Left out: MBRX (no annual filing), CUBT (no annual filing), FBLG (no annual filing). Fiscal periods ending between 2025-06-30 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (CMMB: 20-F), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow CMMB on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to CMMB for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.